



# VET03-A

## Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline

This document provides the most up-to-date techniques for disk diffusion susceptibility testing of aquatic species isolates, and criteria for quality control testing.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in clinical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

## Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Administrative Procedures.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-611-5  
ISSN 0273-3099

VET03-A  
Vol. 26 No. 23  
Formerly M42-A  
Vol. 26 No. 23

## Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline

Volume 26 Number 23

John P. Hawke, PhD  
Renate Reimschuessel, PhD, VMD  
Takashi Aoki, PhD  
Thomas A. Bell, PhD  
Guillaume Blanc, PhD  
Jeremy Carson, PhD  
Beverly Dixon, PhD

Ron A. Miller, MS  
Gilles Olivier, PhD  
Thomas R. Shryock, PhD  
Peter R. Smith, PhD  
Clyde Thornsberry, PhD  
Robert D. Walker, PhD  
Jeffrey L. Watts, PhD, RM (AAM)  
Ching Ching Wu, DVM, PhD

### Abstract

Antimicrobial susceptibility testing is recommended to determine which antimicrobial agents should be considered for treating a bacterial pathogen. Many bacteria that cause disease in aquatic animals require growth conditions that vary substantially from routine terrestrial bacterial pathogens. It has thus become desirable to develop antimicrobial testing standards for organisms that prefer or require conditions such as lower temperatures, semisolid media, or supplemented media (e.g., NaCl, serum).

This guideline describes the standard agar disk diffusion method and quality control criteria for testing Group 1 aquatic bacteria. These organisms can grow readily on standard Mueller-Hinton agar, and are readily cultured at temperatures of  $22 \pm 2$  °C and  $28 \pm 2$  °C. Quality control ranges for *Escherichia coli* ATCC<sup>®</sup> 25922 and *Aeromonas salmonicida* subsp. *salmonicida* ATCC<sup>®</sup> 33658 when tested at 22 °C, 28 °C, and  $35 \pm 2$  °C (*E. coli* only) are listed for different antimicrobial agents used to varying degrees in global aquaculture.

Future editions of this guideline will incorporate additional data, as they become available. Still needed are methods for testing other groups of aquatic pathogens, such as the gliding bacteria, obligate halophiles, and gram-positive cocci. In addition, interpretive criteria will also need to be developed, which requires a correlation between pharmacokinetic/pharmacodynamic properties of the drug, *in vitro* susceptibility data, and clinical outcomes.

Clinical and Laboratory Standards Institute (CLSI). *Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline*. CLSI document VET03-A (ISBN 1-56238-611-5). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2006.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE<sup>®</sup>

Copyright ©2006 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline*. CLSI document VET03-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.

### **Report**

April 2003

### **Proposed Guideline**

August 2005

### **Approved Guideline**

June 2006

ISBN 1-56238-611-5  
ISSN 0273-3099

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Introduction.....	1
3 Definitions .....	2
4 Indications for Performing Susceptibility Testing .....	4
5 Selection of Antimicrobial Agents for Routine Testing and Reporting.....	4
5.1 Routine Reports .....	4
5.2 Antimicrobial Classes .....	5
5.3 Suggested Guidelines for Use and Selective Testing and Reporting.....	6
6 Disk Diffusion Assay Protocol .....	7
6.1 Media Preparation.....	7
6.2 Inoculum .....	8
6.3 Diffusion Disks .....	9
6.4 Incubation .....	10
6.5 Reading Plates.....	11
6.6 Rejection Criteria.....	11
7 Fastidious and Problem Organisms .....	11
7.1 Vibrionaceae and Photobacteriaceae (Obligate Halophilic Strains) (Group 2) .....	12
7.2 Gliding Bacteria (Group 3).....	12
7.3 Streptococci (Group 4).....	13
7.4 Other Fastidious Organisms (Group 5).....	14
8 Quality Control Procedures.....	15
8.1 Purpose .....	15
8.2 Reference Strains for Quality Control .....	15
8.3 Accepted Quality Control Ranges .....	16
8.4 Expansion of Control Strain Set .....	16
8.5 Storing and Testing Quality Control Strains.....	16
8.6 Control of Media and Disks.....	17
8.7 Frequency of Quality Control Testing .....	17
8.8 Corrective Action.....	18
9 Quality Assurance Measures.....	19
References.....	20
Appendix A. Antimicrobial Agents Used in Global Aquaculture and Status of Quality Control for Disk Diffusion Susceptibility Testing .....	24
Appendix B. Fuzzy Zones and Halo Formation .....	26

**Contents (Continued)**

Appendix C. Disk Diffusion Daily Quality Control Testing Protocol .....27

Appendix D. Disk Diffusion Weekly Quality Control Testing Protocol .....28

Table 1. Frequently Isolated Bacterial Pathogens of Fish.....29

Table 2. Solvents and Diluents for Preparation of Stock Solutions of Antimicrobial Agents .....30

Table 3. Standard Methods for Disk Diffusion Susceptibility Testing of Aquatic Bacterial Pathogens .....33

Table 4. Potential Modifications for Disk Diffusion Susceptibility Testing of Aquatic Bacterial Pathogens .....34

Table 5. Acceptable Quality Control Ranges of Zone Diameters (mm) for Reference Strains on Mueller-Hinton Agar (Except Where Noted) at  $35 \pm 2 \text{ }^\circ\text{C}$  .....36

Table 6. Acceptable Quality Control Ranges of Zone Diameters (mm) for *Escherichia coli* ATCC® 25922 When Tested on Mueller-Hinton Agar at  $22 \pm 2 \text{ }^\circ\text{C}$  .....38

Table 7. Acceptable Quality Control Ranges of Zone Diameters (mm) for *Aeromonas salmonicida* subsp. *salmonicida* ATCC® 33658 When Tested on Mueller-Hinton Agar at  $22 \pm 2 \text{ }^\circ\text{C}$  .....39

Table 8. Acceptable Quality Control Ranges of Zone Diameters (mm) for *Escherichia coli* ATCC® 25922 and *Aeromonas salmonicida* subsp. *salmonicida* ATCC® 33658 When Tested on Mueller-Hinton Agar at  $28 \pm 2 \text{ }^\circ\text{C}$  .....40

Summary of Delegate/Consensus Comments and Working Group Responses .....41

The Quality System Approach.....42

Related CLSI/NCCLS Publications.....43

## Foreword

This CLSI guideline represents the collective efforts of the Subcommittee on Veterinary Antimicrobial Susceptibility Testing Aquaculture Working Group (VAST-AWG) to produce a guidance document for standardizing an antimicrobial disk susceptibility test method for bacteria isolated from aquatic species. The working group has relied heavily on the initial efforts of those who organized the *Workshop on MIC Methodologies in Aquaculture, Weymouth, 1998* and the subsequent Alderman and Smith publication of the draft protocols developed at the workshop.<sup>1</sup> These documents outlined the problems encountered when comparing data created by laboratories using different methods, since those data usually varied greatly from laboratory to laboratory. The methods published by Alderman and Smith were termed “tentative” by the authors to indicate there were a number of “unresolved issues.”

Members of the current VAST-AWG have expanded the work of the European group by targeting some of these unresolved issues, such as the development of quality control ranges for quality control strains. We have limited this guideline to the disk diffusion susceptibility testing of Group 1 aquatic organisms (Table 3). This guideline contains the current best thinking of scientists in the field and their recommendations for conducting a particular test. We have not addressed the issues of interpretive criteria. It is hoped that this guideline and the CLSI document M49—*Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals* for broth dilution testing will evolve and include additional standardized susceptibility testing methods and interpretive criteria for antimicrobial agents used to treat bacterial infections in aquatic species.

Since we are attempting to harmonize standards as an international effort, we have chosen to include agents that are used in some nations, but may not be used in other nations. In addition, concerns have been raised about changes in susceptibility of bacteria exposed to antimicrobials in the environment, from either human or veterinary use. It is therefore important to have standardized methods for testing those bacteria isolated from aquatic organisms to drugs used by other medical disciplines. Finally, if more antimicrobials are approved for use in aquaculture—especially those already in use in other areas of agriculture—standards will already be in place.

We have chosen to characterize two quality control strains based on their susceptibility profiles and global availability. *Aeromonas salmonicida* subsp. *salmonicida* (ATCC<sup>®a</sup> 33658; NCIMB<sup>b</sup> 1102) and *Escherichia coli* (ATCC<sup>®</sup> 25922; NCIMB 12210) are both susceptible to a wide range of antimicrobials, grow well at low temperatures, and have proven to be stable after numerous passes on the testing medium. It is proposed that both of these organisms be used as quality control organisms for disk diffusion susceptibility testing. There is a ban on importation of *A. salmonicida* in several nations; *E. coli* may be used in its place.

We have optimized testing conditions primarily for Group 1 (Table 3) organisms and hope that this guideline will engender future studies with other groups of bacteria. Such organisms include the obligate halophilic bacteria and the gliding bacteria, which require specialized media.

The global aquaculture industry is comprised of many fish species, which have substantially different bacterial flora and grow at different temperature optimums. Thus, we have established the quality control ranges at both  $22 \pm 2$  °C and  $28 \pm 2$  °C (Tables 6 through 8). These temperatures were chosen based on temperatures most frequently used for testing, recommendations of the VAST-AWG, and to coordinate efforts with researchers from other countries. In the case of zoonotic pathogens from aquatic sources or tropical fish species, clinicians may request susceptibility data conducted at  $35 \pm 2$  °C. In those cases, refer to Table 5 or CLSI/NCCLS document M31—*Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals*, for the appropriate QC organisms, ranges, and interpretive criteria.

<sup>a</sup> ATCC is a registered trademark of the American Type Culture Collection.

<sup>b</sup> National Collection of Industrial and Marine Bacteria (NCIMB, [www.ukncc.co.uk](http://www.ukncc.co.uk))

## Foreword (Continued)

Since this is a collective effort, recognition must go to the Subcommittee on Veterinary Antimicrobial Susceptibility Testing, especially Thomas Shryock for his help with the CLSI consensus process, and to Robert Walker for his guidance on developing control strains and review of the document. We thank also the present and former members of the Aquaculture Working Group, and the organizers and participants of the *Workshop on MIC Methodologies in Aquaculture, Weymouth, 1998*, who began this process. Special thanks must be given to Ron Miller, whose work has provided the data for the long-awaited criteria for quality control testing. Finally, we must acknowledge the U.S. FDA and Oak Ridge Associated Universities for providing support for this effort.

Renate Reimschuessel, PhD, VMD, *Co-Chairholder*  
John P. Hawke, PhD, *Co-Chairholder*  
Aquaculture Working Group

### *A Note on Terminology*

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, International Organization for Standardization (ISO), and European Committee for Standardization (CEN) documents; and that legally required use of terms, regional usage, and different consensus timelines are all challenges to harmonization. In light of this, CLSI recognizes that harmonization of terms facilitates the global application of standards and is an area of immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

Of particular note in VET03-A are two terms whereby CLSI intends to eliminate confusion, over time, through its commitment to harmonization. For the most part, in this guideline, the term *accuracy* is used correctly in its metrological sense, to refer to the closeness of the agreement between the result of a (single) measurement and a true value of a measurand, thus comprising both random and systematic effects. But there are several instances in this document, where accuracy is defined the way ISO defines *trueness*, i.e., the closeness of the agreement between the average value from a large series of measurements and to a true value of a measurand. To facilitate understanding, when used this way, *trueness* has been inserted parenthetically. Also, the terms are defined in the guideline's Definitions section along with explanatory notes. During the next scheduled revision of this document, they will be reviewed for consistency with international use, and revised appropriately.

This document will most likely be used by aquatic disease diagnosticians who may not be familiar with the CLSI terminology; thus we have included an extensive glossary in this guideline, as well as, in the M49 guideline.

### **Key Words**

Antimicrobial agent, antimicrobial susceptibility testing, aquatic, disk diffusion, veterinary

## **CLSI Working Group on Aquaculture Mission Statement**

To develop and to promote performance standards and interpretive criteria for *in vitro* antimicrobial susceptibility testing of bacteria isolated from aquatic organisms.

## Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline

### 1 Scope

This CLSI guideline provides veterinary and aquatic animal disease diagnostic laboratories with currently recommended antimicrobial disk diffusion susceptibility testing methods for bacteria isolated from aquatic animals—primarily Group 1 organisms—including criteria for quality control testing with two quality control strains.

The document also provides appendixes and tables outlining recommended disk concentrations, antimicrobial agents used in global aquaculture, methods for preparing stock solutions and dilutions of antimicrobial agents, and a list of bacteria pathogenic to fish.

Interpretive criteria are not addressed in this guideline. Such criteria must be established using pharmacokinetic and pharmacodynamic data, *in vitro* susceptibility testing data, and clinical efficacy data. Developing interpretive criteria was beyond the scope of this document. As more aquatic animal-specific information becomes available, this document, and CLSI document M49—*Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals*, will be revised to incorporate those data.

### 2 Introduction

One of the great challenges of fish farming (aquaculture) in the United States is the control of disease outbreaks. Throughout history, various compounds have been used to treat fish maladies, including salt, asphalt, and brandy.<sup>2</sup> During the last century, major advances were made in isolation and identification of microorganisms causing disease in aquatic animals.<sup>3-7</sup> Concurrent with advances in diagnostic techniques came advances in production of antimicrobial substances.<sup>8</sup> The first citations on the use of antimicrobials in fish in the U.S. described the use of sulfa drugs to treat furunculosis in trout.<sup>9,10</sup> The early 1950s, with the inclusion of a veterinary medical branch in the FDA, began the era of governmental regulation of veterinary drugs. To date, only four antimicrobial agents have been approved by the FDA, three of which are available for use in aquaculture fish species: florfenicol to control enteric septicemia in catfish, sulfadimethoxine-ormetoprim to control furunculosis in salmonids and enteric septicemia in catfish; and oxytetracycline monoalkyl trimethyl ammonium for selected indications in salmonids, catfish, and lobsters (see FDA Center for Veterinary Medicine website).<sup>11</sup> Federal regulations, however, permit veterinarians to prescribe extra-label uses of certain approved animal drugs and approved human drugs for minor species. A number of publications describe the use of pharmaceuticals in aquaculture, both for food and ornamental species.<sup>12-14</sup> Extra-label drug use is a practice that occurs in many countries, and governmental agencies worldwide are currently grappling with ways to provide proper veterinary care to minor species.<sup>15</sup> Because of potential extra-label drug use in aquaculture, any standardized methods for determining the susceptibility of microbes isolated from aquatic species must include more drugs than those currently approved for use in aquaculture in any given country. The mention of antimicrobial agents in this document is not an endorsement for their use in fish-farmed species. The use of these highly potent drugs remains subjected to the current regulations in force in their respective countries. For export purposes, the regulations in force in the receiving (importing) country may be consulted.

Aquatic animal diseases, for which antimicrobials may be needed, are too numerous to examine here, but several publications are available that can provide the reader with background.<sup>16-20</sup> Plumb cites our current knowledge of over 70 species of bacteria capable of causing disease in aquaculture.<sup>21</sup> Table 1 includes a short list of the most commonly isolated pathogens. In addition to the organisms well characterized as pathogens of aquatic animals, there are numerous instances where isolated organisms are

either partially identified or unidentified. In such cases, as for identified pathogens, antimicrobial susceptibility testing of the isolates is indicated prior to initiating therapy. Susceptibility tests are also indicated when there is concern that the organism belongs to a bacterial species capable of possessing resistance mechanisms against commonly used antimicrobial agents.

Susceptibility testing of aquatic bacteria that are nonpathogenic is also indicated when examining the epidemiology of resistance in the aquatic environment. There is increasing concern about the potential for public health impacts following antimicrobial use in aquaculture.<sup>22-26</sup> These concerns are due, in part, to detection of antimicrobial agent residues in sediment from fish farms,<sup>27-29</sup> and to the occurrence of bacteria resistant to antimicrobials following their use on fish farms.<sup>30,31</sup> Much of this literature reports data derived using a variety of antimicrobial susceptibility testing protocols. These procedures vary in the incubation temperature and duration, as well as media and antibiotic concentration. In order to adequately assess the effect antimicrobial use has on aquatic environmental bacteria, it is essential that standardized methods be developed and used.

### 3 Definitions

**absorbance (A)//optical density (OD)** – *in optics* **1)** the capacity of a substance to absorb radiation; **NOTE:** Expressed as the logarithm of the reciprocal of the transmittance of the substance;  $A = \log(1/T) = -\log(T)$  (ASTM8-94)<sup>32</sup>; **2) decadic absorbance** – the negative decadic logarithm of one minus the absorbance.

**antimicrobial susceptibility test interpretive category – 1)** a classification based on an *in vitro* response of an organism to an antimicrobial agent at levels of that agent corresponding to blood or tissue levels attainable with usually prescribed doses of that agent; **2) susceptible antimicrobial susceptibility test interpretive category** – a category that implies that an infection due to the isolate may be appropriately treated with the dosage regimen of an antimicrobial agent recommended for that type of infection and infecting species, unless otherwise indicated; **3) intermediate antimicrobial susceptibility test interpretive category** – a category that implies that an infection due to the isolate may be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used; also indicates a "buffer zone" that should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations; **4) resistant antimicrobial susceptibility test interpretive category** – resistant isolates are not inhibited by the usually achievable concentrations of the agent with normal dosage schedules and/or fall in the range where specific microbial resistance mechanisms are likely (e.g., beta-lactamases), and clinical efficacy has not been reliable in treatment studies.

**colorimeter** – an instrument used for color measurement based on optical comparison with standard colors (ASTM8-94).<sup>32</sup>

**concentration – 1)** a measure of the amount of dissolved substance per unit of volume (RHUD1.7CD93)<sup>33</sup>; **2) mass concentration**, kg/L – the mass of component divided by the volume of the system containing the component (IUPAC/IFCC1978-4.8)<sup>34</sup>; **3) substance concentration**, mol/L – the amount of substance {mol} of the component divided by the volume of the system (IUPAC/IFCC1978-4.11).<sup>34</sup>

**consensus** – *in CLSI documents*, the substantial agreement by materially affected, competent, and interested parties that is obtained by following the procedures specified for CLSI consensus approval; **NOTE:** CLSI consensus does not always connote unanimous agreement, but it does mean that the participants in the development of a standard or guideline have considered and resolved all relevant comments and are willing to abide by the resulting agreement.

**control material//control** – a device, solution, or lyophilized preparation intended for use in the quality control process; **NOTE 1:** The expected reaction or concentration of analytes of interest are known within

## The Quality System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The approach is based on the model presented in the most current edition of CLSI/NCCLS document HS1—*A Quality Management System Model for Health Care*. The quality management system approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any healthcare service’s path of workflow (i.e., operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The quality system essentials (QSEs) are:

- |   |   |  |   |
|---|---|--|---|
| Documents & Records Organization<br>Personnel | Equipment Purchasing & Inventory<br>Process Control | Information Management Occurrence Management<br>Assessment | Process Improvement Service & Satisfaction<br>Facilities & Safety |
|---|---|--|---|

VET03-A addresses the quality system essentials (QSEs) indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI/NCCLS Publications section on the following page.

Documents & Records	Organization	Personnel	Equipment	Purchasing & Inventory	Process Control	Information Management	Occurrence Management	Assessment	Process Improvement	Service & Satisfaction	Facilities & Safety
					X M2 M6 M7 M23 M37 M49						

Adapted from CLSI/NCCLS document HS1—*A Quality Management System Model for Health Care*.

### Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, CLSI/NCCLS document GP26—*Application of a Quality Management System Model for Laboratory Services*, defines a clinical laboratory path of workflow which consists of three sequential processes: preexamination, examination, and postexamination. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

VET03-A addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI/NCCLS Publications section on the following page.

Preexamination				Examination			Postexamination	
Examination ordering	Sample collection	Sample transport	Sample receipt/processing	Examination	Results review and follow-up	Interpretation	Results reporting and archiving	Sample management
					X M2 M7 M31 M49	X M2 M31 M49	X M2 M7 M31 M49	

Adapted from CLSI/NCCLS document HS1—*A Quality Management System Model for Health Care*.

## Related CLSI/NCCLS Publications\*

- M2-A9**      **Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Ninth Edition (2006).** This document contains the current Clinical and Laboratory Standards Institute-recommended methods for disk susceptibility testing, criteria for quality control testing, and updated tables for interpretive zone diameters.
- M6-A2**      **Protocols for Evaluating Dehydrated Mueller-Hinton Agar; Approved Standard—Second Edition (2006).** This document provides procedures for evaluating production lots of dehydrated Mueller-Hinton agar, and for developing and applying reference media.
- M7-A7**      **Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Seventh Edition (2006).** This document addresses reference methods for the determination of minimal inhibitory concentrations (MICs) of aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution.
- M23-A2**     **Development of *In Vitro* Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline—Second Edition (2001).** This document addresses the required and recommended data needed for the selection of appropriate interpretive standards and quality control guidelines for antimicrobial agents.
- M31-A2**     **Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard—Second Edition (2002).** This document provides the currently recommended techniques for antimicrobial agent disk and dilution susceptibility testing, criteria for quality control testing, and interpretive criteria for veterinary use.
- M37-A2**     **Development of *In Vitro* Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline—Second Edition (2002).** This document addresses the required and recommended data needed for selection of appropriate interpretive standards and quality control guidelines for new veterinary antimicrobial agents.
- M49-A**      **Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Approved Guideline (2006).** This document provides the most up-to-date techniques for the determination of minimal inhibitory concentrations (MICs) of aquatic bacteria by broth micro- and macrodilution, and criteria for quality control testing.

---

\* Proposed-level documents are being advanced through the Clinical and Laboratory Standards Institute consensus process; therefore, readers should refer to the most current editions.



# Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we're adding initiatives to bring even more value to our members and customers.



## Shop Our Online Products

Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.



## Find Membership Opportunities

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.



## Visit the CLSI U Education Center

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.



## Shop Our Online Products

Including eCLIPSE Ultimate Access™, CLSI's cloud-based, online portal that makes it easy to access our standards and guidelines—*anytime, anywhere.*

For more information, visit [www.clsi.org](http://www.clsi.org) today.

SAMPLE



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

950 West Valley Road, Suite 2500, Wayne, PA 19087 USA

P: 610.688.0100 Toll Free (US): 877.447.1888 F: 610.688.0700

E: [customerservice@clsi.org](mailto:customerservice@clsi.org) [www.clsi.org](http://www.clsi.org)

ISBN 1-56238-611-5